Plain-English translation of NCT04271644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called BCMA-targeted CAR-T cell therapy for people with multiple myeloma (a blood cancer) that has come back or stopped responding to standard drugs. Researchers will collect some of your immune cells, modify them in the laboratory to recognize and attack cancer cells, and then give them back to you. The goal is to see if this approach is safe and whether it helps control your cancer.
Multiple myeloma that returns or becomes resistant to standard treatments is very difficult to manage, and treatment options are limited. This medication targets a protein called BCMA that appears on most myeloma cancer cells, offering a new way to help patients when other treatments stop working.
You likely qualify if…
You likely don't qualify if…
If you join this study, doctors will collect some of your blood cells and send them to a laboratory where they will be modified to recognize your cancer cells. While your cells are being prepared—a process that typically takes a few weeks—you may receive chemotherapy to prepare your body. Once your modified cells are ready, you will receive them back through an infusion. You will then be closely monitored with blood tests, imaging, and clinic visits to check for side effects and to see how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China